Latest Intelligence in Canada

Published within

« | ... | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

V&S Group: cutting through the clutter

After experiencing phenomenal growth during the early days, manufacturers' and consumers' enthusiasm for the RTD market has since waned, especially in recognition of growing market clutter. However, the V&S Group's focus on taste and image in designing Absolut Cut should ensure a positive reception, particularly in Europe.

Published By Datamonitor
27 Apr 2004
CommentWire
CommentWire

GW Pharmaceuticals: high expectations for cannabis drug

GW Pharmaceuticals [GWP.L] and Bayer Healthcare [BAY.F] have submitted a New Drug Submission for Sativex, a cannabis-based medicine for the symptomatic treatment of multiple sclerosis (MS) and neuropathic pain, to Health Canada. This move will help generate optimism regarding Sativex, offering renewed hope for manufacturers and patients alike.

Published By Datamonitor
13 May 2004
CommentWire
CommentWire

Molson: family dispute leaves future uncertain

While Molson [MOLA.TO] has been a Canadian brewing icon for 218 years, board-level arguments, poorly performing subsidiaries and lackluster North American sales have raised question marks over the company's future. It may yet need to form a partnership with a larger rival to compete in an increasingly consolidated beer market.

Published By Datamonitor
24 Jun 2004
CommentWire
CommentWire

Molson: a merger brewing

Both Coors [RKY] and Molson [MOLA.TO] have suffered in their core North American markets as consumers increasingly go for the low-carb and light beers offered by rivals such as Anheuser-Busch [BUD]. There remains some doubt as to whether a merger between the two will do much to improve their standing in a cutthroat market.

Published By Datamonitor
23 Jul 2004
Expert View
Expert View

US online pharmacies can attract consumers from cross-border discounters

The trade in discounted prescription drugs between Canada and the US has elicited considerable controversy on both sides of the border. Yet recent figures show that sales of drugs via Canadian pharmacies have not been as great as some had predicted. However, as Datamonitor's David Deon explains, pharmaceutical companies could go further by driving the expansion of online prescribing in the US...

Published By Datamonitor
28 Jul 2004
CommentWire
CommentWire

Molson Coors: a new team

Both Molson and Coors have close links with their own nations' favorite sporting pastimes. New marketing opportunities will be explored soon enough and combining forces may allow the new Molson Coors to build market share in both the US and Canada. However, as sport and national patriotism often go hand in hand, continuing with a dual brand marketing approach may prove most successful.

Published By Datamonitor
29 Jul 2004
CommentWire
CommentWire

Wal-Mart: the state of the union

An outlet in Quebec, Canada has become one of the first Wal-Mart [WMT] stores in North America to obtain union certification. Famous for its low prices and infamous for its lower wages, Wal-Mart has long opposed such a move. In light of recent negative publicity, however, resisting unionization could create more woes for the retail giant.

Published By Datamonitor
05 Aug 2004
Expert View
Expert View

Isotechnika's search for a partner continues

Isotechnika's Q2 loss shows a sharp reversal in fortunes. Profit in 2003 was largely attributable to a research payment for ISA247 from Roche, which has since pulled out of part of the deal. Isotechnika will be hoping that Roche continues to support ISA247 in the field of transplantation, but, says Datamonitor's Timothy Pang, it would be boosted by the cash that a new partner would bring...

Published By Datamonitor
13 Aug 2004
CommentWire
CommentWire

UK energy: nuclear option key to supply diversity

With increasing demand for energy, restricted supply, and Kyoto targets on reducing greenhouse gas emissions to meet, the case for building new nuclear plants, once dismissed as a last resort, is rapidly regaining force. The importance of the nuclear role as part of a diverse generation portfolio must not be underestimated.

Published By Datamonitor
15 Sep 2004
CommentWire
CommentWire

Biovail: court case may dent Wellbutrin revenues

Taiwan-based generics manufacturer Anchen Pharmaceuticals has submitted an abbreviated new drug application (ANDA) to the FDA for Biovail's [BVF.TO] Wellbutrin XL (bupropion). Should the application be accepted, Biovail, already suffering from the effects of generic competition from other variants of the brand, would face further revenue decline.

Published By Datamonitor
18 Nov 2004

« | ... | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | ... | » »|

No help is available.